Designing information systems to support program activities requires an analysis of what is done and by whom throughout the process. To this end, PHII convened a workgroup in February and March 2008 to carry out the business process analysis (BPA) of NDBS from birth through long-term follow-up. This work is supported by PHII in partnership with the Health Resources and Services Administration, Maternal and Child Health Bureau (HRSA/MCHB) and the Genetics and Newborn Screening Region 3 Collaborative (Region 3).

Disclaimer: PHII developed this resource on January 2, 2008. Best practices on this subject may have since evolved, and we encourage our audience to do individual research to evaluate its relevance.

PHII (December 3, 2022) Newborn Dried Bloodspot Screening Business Process Analysis. Retrieved from https://phii.org/resources/newborn-dried-bloodspot-screening-business-process-analysis/.
"Newborn Dried Bloodspot Screening Business Process Analysis." PHII - December 3, 2022, https://phii.org/resources/newborn-dried-bloodspot-screening-business-process-analysis/
PHII January 2, 2008 Newborn Dried Bloodspot Screening Business Process Analysis., viewed December 3, 2022,<https://phii.org/resources/newborn-dried-bloodspot-screening-business-process-analysis/>
PHII - Newborn Dried Bloodspot Screening Business Process Analysis. [Internet]. [Accessed December 3, 2022]. Available from: https://phii.org/resources/newborn-dried-bloodspot-screening-business-process-analysis/
"Newborn Dried Bloodspot Screening Business Process Analysis." PHII - Accessed December 3, 2022. https://phii.org/resources/newborn-dried-bloodspot-screening-business-process-analysis/
"Newborn Dried Bloodspot Screening Business Process Analysis." PHII [Online]. Available: https://phii.org/resources/newborn-dried-bloodspot-screening-business-process-analysis/. [Accessed: December 3, 2022]

Resource Files

Related Resources

Birth Defects Surveillance

STI Connect: Clinical Decision Support

Digital Tools in Support of Contact Tracing for COVID-19